Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients
Table 1
Clinical characteristics of patients (n = 564).
Characteristics
All patients, n (%)
Training cohort, n (%)
Validation cohort, n (%)
valuea
Total
564
376
188
Gender
Male
282 (50.0)
191 (50.8)
91 (48.4)
0.592
Female
282 (50.0)
185 (49.2)
97 (51.6)
Age
≤60
320 (56.7)
208 (55.3)
112 (59.6)
0.336
>60
244 (43.3)
168 (44.7)
76 (40.4)
COO
GCB
278 (49.3)
177 (47.1)
101 (53.7)
0.137
Non-GCB
286 (50.7)
199 (52.9)
87 (46.3)
Ki-67 (%)
≥90
135 (23.9)
87 (24.8)
48 (26.5)
0.530
<90
429 (76.1)
289 (75.2)
140 (73.5)
B symptoms
Presence
289 (51.2)
190 (50.6)
99 (52.7)
0.634
Absence
275 (48.8)
186 (49.4)
89 (47.3)
ECOG
0-1
288 (51.1)
190 (50.1)
88 (46.8)
0.810
>1
276 (48.9)
186 (49.9)
90 (53.2)
Bulky disease
Presence
77 (13.7)
48 (12.8)
29 (15.4)
0.386
Absence
487 (86.3)
328 (87.2)
159 (84.6)
Ann Arbor
I-II
158 (28.0)
103 (27.4)
55 (31.2)
0.643
III-IV
406 (72.0)
273 (72.6)
133 (68.8)
No. of extranodal sites
0-1
462 (81.9)
315 (83.8)
155 (87.1)
0.998
>1
102 (18.1)
61 (16.2)
30 (12.9)
BM involvement
Presence
71 (12.6)
44 (11.7)
27 (15.2)
0.369
Absence
493 (87.4)
332 (88.3)
161 (84.8)
CNS involvement
Presence
36 (6.4)
24 (7.2)
12 (6.8)
1
Absence
528 (93.6)
352 (92.8)
176 (93.2)
LDH
Elevated
254 (45.0)
169 (44.9)
85 (48.3)
0.952
Normal
310 (55.0)
207 (55.1)
103 (51.7)
Alb
Low
167 (29.6)
109 (30.0)
58 (33.0)
0.648
Normal
397 (70.4)
267 (70.0)
130 (67.0)
LMR
Lowb
223 (39.5)
144 (38.3)
79 (44.9)
0.394
High
341 (60.5)
232 (61.7)
109 (55.1)
D-dimer
c > 0.87
332 (58.9)
223 (59.3)
109 (61.9)
0.762
≤0.87
232 (41.1)
153 (40.7)
79 (38.1)
HBsAg
Positive
48 (8.5)
34 (9.0)
14 (8.0)
0.522
Negative
516 (91.5)
342 (91.0)
174 (92.0)
IPI
0-1
159 (28.2)
108 (28.7)
51 (27.1)
0.928
2
119 (21.1)
80 (21.3)
39 (20.7)
3
125 (22.2)
84 (22.3)
41 (21.8)
4-5
161 (28.5)
104 (27.7)
57 (30.3)
LMR, lymphocyte-monocyte ratio; BM, bone marrow; CNS, central nervous system; COO, cell of origin; ECOG, Eastern Cooperative Oncology Group; atraining cohort vs. validation cohort, P value was calculated by the Pearson Chi-square test, and is regarded significant. b<2.5.
